** Shares of vaccine maker Moderna MRNA.O gain 1.9% to $43.18 premarket
** Co has been awarded tender to supply its mRNA COVID-19 vaccine in the European Union, Norway and North Macedonia, allowing 17 countries to access the vaccine for up to four years
** Tender comes after MRNA cut its 2025 sales forecast by $1 bln earlier this month, partially due to weak demand for its COVID-19 vaccines
** The trim brought co's FY25 revenue forecast below analysts' estimates and sent shares down nearly 17% on Jan. 13
** Seven of 26 brokerages covering stock rate it "buy", 15 rate "hold" and four rate "sell" or lower; median PT is $57 - LSEG data
** MRNA stock more than halved in 2024
(Reporting by Sanchayaita Roy in Bengaluru)
((Sanchayaita.roy@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.